

## Special Issue

# African Swine Fever Virus Prevention and Control

### Message from the Guest Editor

Since its introduction into Georgia in 2007, African swine fever virus has spread across both Europe and Asia and has been responsible for the deaths of hundreds of millions of animals. Virulent strains of the virus cause a haemorrhagic fever to occur in domestic pigs and wild boar that is invariably fatal. The main tools missing from the African swine fever control kit are vaccines suitable for preventing disease in both domestic and wild animals. Without such vaccines, it is difficult to envisage how the current epidemic can be brought under control and the disease eradicated. Novel approaches are required, as, to date, inactivated viruses and attenuation through tissue culture passage have not yielded safe and effective vaccines. Due to the severity of the current African swine fever virus epidemic, alternative strategies including prophylaxis may also need to be considered. Deployment of such novel control strategies will require the development of effective implementation strategies based on robust epidemiological modeling.

### Guest Editor

Dr. Christopher Netherton

african Swine Fever Vaccinology Group, The Pirbright Institute, Surrey  
GU24 0NF, UK

### Deadline for manuscript submissions

closed (31 January 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/39062](https://mdpi.com/si/39062)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).